Furthermore, we used linagliptin in the present study, because linagliptin has a unique xanthine-based structure and takes the advantage of being used in patients with renal dysfunction without dose adjustment in contrast to other approved DPP-4 inhibitors [22,23]. The gene discussed is DPP4; the disease is Abnormal renal physiology.